Global Selective Cox-2 Inhibitors Market Research Report 2024, Forecast to 2029
Cox-2 inhibitor: An antiinflammatory drug that selectively blocks the cox-2 enzyme. Blocking this enzyme impedes the production of the chemical messengers that cause the pain and swelling of arthritis inflammation.
Our market research covers global as well as regional markets and provides an in-depth analysis of the overall growth prospects of the market. Global market trend analysis including historical data, estimates to 2024, and compound annual growth rate (CAGR) forecast to 2029 is given based on qualitative and quantitative analysis of the market segments involving economic and non-economic factors. Furthermore, it reveals the comprehensive competitive landscape of the global market, the current and future market prospects of the industry, and the growth opportunities and drivers as well as challenges and constraints in emerging and emerging markets.
We can meet the customized needs of customers in multiple dimensions, in-depth and high quality, help customers accurately grasp market opportunities, easily deal with market challenges, properly formulate market strategies, and act quickly to win sufficient market competition time and space for customers.
Projected and forecast revenue values are in constant U.S. dollars, unadjusted for inflation.
The global economy and markets have been remarkably resilient in the face of tightening financial conditions and geopolitical upheaval over the past few years, with economic growth holding up better than most analysts’ expectations.
The global environment has still not settled onto a clear pathway toward a new stability as we enter 2024. In this disjointed world, we confront risks posed by potential volatility across the economic and political spheres. We also see potential opportunities arising from the new reality of greatly segmented global relationships.
We have identified five overlapping themes that will drive global political and economic relationships in 2024: geopolitical reordering, economic fault lines, resource security, supply chain resilience and logistics rewired.
The report will conduct a comprehensive and professional analysis of the Selective Cox-2 Inhibitors market in 2024 based on the current situation, global economic impact and other aspects.
Market Segment by Product Type
Meloxicam
Celecoxib
Etoricoxib
Imrecoxib
Etodolac
Parecoxib
Other
Market Segment by Product Application
Rheumatoid Arthritis
Osteoarthritis
Spondylosis Chronica Ankylopoietica
Other
Finally, the report provides detailed profile and data information analysis of leading company.
Boehringer-Ingelheim
TerSera Therapeutics
Iroko Pharmaceuticals
Apotex
Yung Shin Pharmaceutical
Breckenridge Pharmaceutical
Meda Pharmaceuticals
Cipla
Glenmark Pharmaceuticals
Teva
PuraCap Pharmaceutical
Almirall Limited
Lupin Pharmaceuticals
Aurobindo Pharma
Pfizer
Mylan
Shire Pharmaceuticals
Bayer
Novacap
Abbott
Geri-Care
Perrigo
Kopran
Merck
Hengrui pharmaceutical
Kelun Group
Qilu Pharmaceutical
Taro Pharmaceuticals
Insights and Tools:
This report provides industry-standard analytical accuracy and high data completeness to uncover key opportunities available in the global industry market. Buyers of the report can obtain verified and reliable market forecasts, including revenue forecasts for the overall size of the global industry market.
The report is an effective tool for players to gain a competitive advantage over their competitors and ensure lasting success in the industry market. All findings, data, and information presented in the report have been verified and re-verified with the help of reliable sources. The analysts who authored the report have taken a unique approach to industry-best research and analysis for an in-depth study of the global industry market.
Use both primary and secondary data sources when compiling reports. Primary sources include extensive interviews with key opinion leaders and industry experts such as experienced front-line employees, directors, CEOs and marketing executives, downstream distributors as well as end users. Secondary sources include research on top companies' annual and financial reports, public documents, new journals, and more. We also work with some third-party databases.
The market research includes historical and forecast data from like demand, application details, price trends, and company shares by geography, especially focuses on the key regions like United States, European Union, China, and other regions.
Research Objectives
1.To define, describe and forecast the Selective Cox-2 Inhibitors market by type, application, end user and region
2.Provide enterprise external environment analysis and SWOT analysis
3.Focuses on the key global Selective Cox-2 Inhibitors manufacturers, to define, describe and analyze the value, market share, market competition landscape, Porter's five forces analysis, and development plans in next few years.
4.Provide market entry strategy analysis for new players or players preparing to enter the market
5.Keep up with international market trends and analyze the impact of the important international events on major global regions
6.Analyze market opportunities for stakeholders to provide market leaders with detailed information on the competitive landscape
Global Selective Cox-2 Inhibitors Market Research Report 2024, Forecast to 2029
1 Market Study Overview
1.1 Study Objectives
1.2 Selective Cox-2 Inhibitors Introduce
1.3 Combined with the Analysis of Macroeconomic Indicators
1.4 Brief Description of Research methods
1.5 Market Breakdown and Data Triangulation
2 Global Trend Summary
2.1 Selective Cox-2 Inhibitors Segment by Type
2.1.1 Meloxicam
2.1.2 Celecoxib
2.1.3 Etoricoxib
2.1.4 Imrecoxib
2.1.5 Etodolac
2.1.6 Parecoxib
2.1.7 Other
2.2 Market Analysis by Application
2.2.1 Rheumatoid Arthritis
2.2.2 Osteoarthritis
2.2.3 Spondylosis Chronica Ankylopoietica
2.2.4 Other
2.3 Global Selective Cox-2 Inhibitors Market Comparison by Regions (2019-2029)
2.3.1 Global Selective Cox-2 Inhibitors Market Size (2019-2029)
2.3.2 North America Selective Cox-2 Inhibitors Status and Prospect (2019-2029)
2.3.3 Europe Selective Cox-2 Inhibitors Status and Prospect (2019-2029)
2.3.4 China Selective Cox-2 Inhibitors Status and Prospect (2019-2029)
2.3.5 Japan Selective Cox-2 Inhibitors Status and Prospect (2019-2029)
2.3.6 Southeast Asia Selective Cox-2 Inhibitors Status and Prospect (2019-2029)
2.4 Basic Product Information
2.4.1 Basic Product Information & Technology Development History
2.4.2 Product Manufacturing Process
2.4.3 Interview with Major Market Participants
2.4.4 High-end Market Analysis and Forecast
2.5 Coronavirus Disease 2020 (Covid-19): Selective Cox-2 Inhibitors Industry Impact
2.5.1 Selective Cox-2 Inhibitors Business Impact Assessment - Covid-19
2.5.2 Market Trends and Selective Cox-2 Inhibitors Potential Opportunities in the COVID-19 Landscape
2.5.3 Measures / Proposal against Covid-19
3 Competition by Manufacturer
3.1 Global Selective Cox-2 Inhibitors Sales and Market Share by Manufacturer (2019-2024)
3.2 Global Selective Cox-2 Inhibitors Revenue and Market Share by Manufacturer (2019-2024)
3.3 Global Selective Cox-2 Inhibitors Industry Concentration Ratio (CR5 and HHI)
3.4 Top 5 Selective Cox-2 Inhibitors Manufacturer Market Share
3.5 Top 10 Selective Cox-2 Inhibitors Manufacturer Market Share
3.6 Date of Key Manufacturers Enter into Selective Cox-2 Inhibitors Market
3.7 Key Manufacturers Selective Cox-2 Inhibitors Key Manufacturers
3.8 Mergers & Acquisitions Planning
4 Analysis of Selective Cox-2 Inhibitors Industry Key Manufacturers
4.1 Boehringer-Ingelheim
4.1.1 Compan Detail
4.1.2 Boehringer-Ingelheim Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.1.3 Boehringer-Ingelheim 178 Sales, Price, Cost, Gross Margin, and Revenue (2019-2024)
4.1.4 Main Business Overview
4.1.5 Boehringer-Ingelheim News
4.2 TerSera Therapeutics
4.2.1 Compan Detail
4.2.2 TerSera Therapeutics Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.2.3 TerSera Therapeutics Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2019-2024)
4.2.4 Main Business Overview
4.2.5 Boehringer-Ingelheim News
4.3 Iroko Pharmaceuticals
4.3.1 Compan Detail
4.3.2 Iroko Pharmaceuticals Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.3.3 Iroko Pharmaceuticals Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2019-2024)
4.3.4 Main Business Overview
4.3.5 Iroko Pharmaceuticals News
4.4 Apotex
4.4.1 Compan Detail
4.4.2 Apotex Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.4.3 Apotex Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2019-2024)
4.4.4 Main Business Overview
4.4.5 Apotex News
4.5 Yung Shin Pharmaceutical
4.5.1 Compan Detail
4.5.2 Apotex Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.5.3 Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2019-2024)
4.5.4 Main Business Overview
4.5.5 Yung Shin Pharmaceutical News
4.6 Breckenridge Pharmaceutical
4.6.1 Compan Detail
4.6.2 Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.6.3 Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2019-2024)
4.6.4 Main Business Overview
4.6.5 Breckenridge Pharmaceutical News
4.7 Meda Pharmaceuticals
4.7.1 Compan Detail
4.7.2 Meda Pharmaceuticals Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.7.3 Meda Pharmaceuticals Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2019-2024)
4.7.4 Main Business Overview
4.7.4 Main Business Overview
4.8 Cipla
4.8.1 Compan Detail
4.8.2 Cipla Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.8.3 Cipla Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2019-2024)
4.8.4 Main Business Overview
4.8.5 Cipla News
4.9 Glenmark Pharmaceuticals
4.9.1 Compan Detail
4.9.2 Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.9.3 Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2019-2024)
4.9.4 Main Business Overview
4.9.5 Glenmark Pharmaceuticals News
4.10 Teva
4.10.1 Compan Detail
4.10.2 Teva Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.10.3 Teva Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2019-2024)
4.10.4 Main Business Overview
4.10.5 Teva News
4.11 PuraCap Pharmaceutical
4.11.1 Compan Detail
4.11.2 PuraCap Pharmaceutical Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.11.3 PuraCap Pharmaceutical Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2019-2024)
4.11.4 Main Business Overview
4.11.5 PuraCap Pharmaceutical News
4.12 Almirall Limited
4.12.1 Compan Detail
4.12.2 Almirall Limited Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.12.3 Almirall Limited Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2019-2024)
4.12.4 Main Business Overview
4.12.5 Almirall Limited News
4.13 Lupin Pharmaceuticals
4.13.1 Company Details
4.13.2 Lupin Pharmaceuticals Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.13.3 Lupin Pharmaceuticals Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2019-2024)
4.13.4 Main Business Overview
4.13.5 Lupin Pharmaceuticals News
4.14 Aurobindo Pharma
4.14.1 Compan Detail
4.14.2 Aurobindo Pharma Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.14.3 Aurobindo Pharma Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2019-2024)
4.14.4 Main Business Overview
4.14.5 Aurobindo Pharma News
4.15 Pfizer
4.15.1 Compan Detail
4.15.2 Pfizer Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.15.3 Pfizer Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2019-2024)
4.15.4 Main Business Overview
4.15.5 Pfizer News
4.16 Mylan
4.16.1 Compan Detail
4.16.2 Mylan Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.16.3 Mylan Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2019-2024)
4.16.4 Main Business Overview
4.16.5 Mylan News
4.17 Shire Pharmaceuticals
4.17.1 Compan Detail
4.17.2 Shire Pharmaceuticals Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.17.3 Shire Pharmaceuticals Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2019-2024)
4.17.4 Main Business Overview
4.17.5 Shire Pharmaceuticals News
4.18 Bayer
4.18.1 Compan Detail
4.18.2 Bayer Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.18.3 Bayer Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2019-2024)
4.18.4 Main Business Overview
4.18.5 Bayer News
4.19 Novacap
4.19.1 Compan Detail
4.19.2 Novacap Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.19.3 Novacap Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2019-2024)
4.19.4 Main Business Overview
4.19.5 Novacap News
4.20 Abbott
4.20.1 Compan Detail
4.20.2 Abbott Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.20.3 Abbott Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2019-2024)
4.20.4 Main Business Overview
4.20.5 Abbott News
4.21 Geri-Care
4.21.1 Compan Detail
4.21.2 Geri-Care Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.21.3 Geri-Care Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2019-2024)
4.21.4 Main Business Overview
4.21.5 Geri-Care News
4.22 Perrigo
4.22.1 Compan Detail
4.22.2 Perrigo Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.22.3 Perrigo Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2019-2024)
4.22.4 Main Business Overview
4.22.5 Perrigo News
4.23 Kopran
4.23.1 Compan Detail
4.23.2 Kopran Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.23.3 Kopran Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2019-2024)
4.23.4 Main Business Overview
4.23.5 Kopran News
4.24 Merck
4.24.1 Compan Detail
4.24.2 Merck Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.24.3 Merck Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2019-2024)
4.24.4 Main Business Overview
4.24.5 Merck News
4.25 Hengrui pharmaceutical
4.25.1 Compan Detail
4.25.2 Hengrui pharmaceutical Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.25.3 Hengrui pharmaceutical Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2019-2024)
4.25.4 Main Business Overview
4.25.5 Hengrui pharmaceutical News
4.26 Kelun Group
4.26.1 Compan Detail
4.26.2 Kelun Group Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.26.3 Kelun Group Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2019-2024)
4.26.4 Main Business Overview
4.26.5 Kelun Group News
4.27 Qilu Pharmaceutical
4.27.1 Compan Detail
4.27.2 Qilu Pharmaceutical Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.27.3 Qilu Pharmaceutical Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2019-2024)
4.27.4 Main Business Overview
4.27.5 Qilu Pharmaceutical News
4.28 Taro Pharmaceuticals
4.28.1 Compan Detail
4.28.2 Taro Pharmaceuticals Selective Cox-2 Inhibitors Product Introduction, Application and Specification
4.28.3 Taro Pharmaceuticals Selective Cox-2 Inhibitors Sales, Price, Cost, Gross Margin, and Revenue (2019-2024)
4.28.4 Main Business Overview
4.28.5 Taro Pharmaceuticals News
5 Global Selective Cox-2 Inhibitors Market Segment by Big Type
5.1 Global Selective Cox-2 Inhibitors Revenue, Sales and Market Share by Big Type (2019-2024)
5.1.1 Global Selective Cox-2 Inhibitors Sales and Market Share by Big Type (2019-2024)
5.1.2 Global Selective Cox-2 Inhibitors Revenue and Market Share by Big Type (2019-2024)
5.2 Meloxicam Sales Growth Rate and Price
5.2.1 Global Meloxicam Sales Growth Rate (2019-2024)
5.2.2 Global Meloxicam Price (2019-2024)
5.3 Celecoxib Sales Growth Rate and Price
5.3.1 Global Celecoxib Sales Growth Rate (2019-2024)
5.3.2 Global Celecoxib Price (2019-2024)
5.4 Etoricoxib Sales Growth Rate and Price
5.4.1 Global Etoricoxib Sales Growth Rate (2019-2024)
5.4.2 Global Etoricoxib Price (2019-2024)
5.5 Imrecoxib Sales Growth Rate and Price
5.5.1 Global Imrecoxib Sales Growth Rate (2019-2024)
5.5.2 Global Imrecoxib Price (2019-2024)
5.6 Etodolac Sales Growth Rate and Price
5.6.1 Global Etodolac Sales Growth Rate (2019-2024)
5.6.2 Global Etodolac Price (2019-2024)
5.7 Parecoxib Sales Growth Rate and Price
5.7.1 Global Parecoxib Sales Growth Rate (2019-2024)
5.7.2 Global Parecoxib Price (2019-2024)
5.8 Other Sales Growth Rate and Price
5.8.1 Global Other Sales Growth Rate (2019-2024)
5.8.2 Global Other Price (2019-2024)
6 Global Selective Cox-2 Inhibitors Market Segment by Big Application
6.1 Global Selective Cox-2 Inhibitors Sales Market Share by Big Application (2019-2024)
6.2 Rheumatoid Arthritis Sales Growth Rate (2019-2024)
6.3 Osteoarthritis Sales Growth Rate (2019-2024)
6.4 Spondylosis Chronica Ankylopoietica Sales Growth Rate (2019-2024)
6.5 Other Sales Growth Rate (2019-2024)
7 Global Selective Cox-2 Inhibitors Forecast
7.1 Global Selective Cox-2 Inhibitors Revenue, Sales and Growth Rate (2024-2029)
7.2 Selective Cox-2 Inhibitors Market Forecast by Regions (2024-2029)
7.2.1 North America Selective Cox-2 Inhibitors Market Forecast (2024-2029)
7.2.2 Europe Selective Cox-2 Inhibitors Market Forecast (2024-2029)
7.2.3 China Selective Cox-2 Inhibitors Market Forecast (2024-2029)
7.2.4 Japan Selective Cox-2 Inhibitors Market Forecast (2024-2029)
7.2.5 Southeast Asia Selective Cox-2 Inhibitors Market Forecast (2024-2029)
7.2.6 Other Regions Selective Cox-2 Inhibitors Market Forecast (2024-2029)
7.3 Selective Cox-2 Inhibitors Market Forecast by Type (2024-2029)
7.3.1 Global Selective Cox-2 Inhibitors Sales Forecast by Type (2024-2029)
7.3.2 Global Selective Cox-2 Inhibitors Market Share Forecast by Type (2024-2029)
7.4 Selective Cox-2 Inhibitors Market Forecast by Application (2024-2029)
7.4.1 Global Selective Cox-2 Inhibitors Sales Forecast by Application (2024-2029)
7.4.2 Global Selective Cox-2 Inhibitors Market Share Forecast by Application (2024-2029)
8 Market Analysis
8.1.1 Market Overview
8.1.2 Market Opportunities
8.1.3 Market Risk
8.1.4 Market Driving Force
8.1.5 Porter's Five Forces Analysis
8.1.6 SWOT Analysis
9 Selective Cox-2 Inhibitors Related Market Analysis
9.1 Upstream Analysis
9.1.1 Macro Analysis of Upstream Markets
9.1.2 Key Players in Upstream Markets
9.1.3 Upstream Market Trend Analysis
9.1.4 Selective Cox-2 Inhibitors Manufacturing Cost Analysis
9.2 Downstream Market Analysis
9.2.1 Macro Analysis of Down Markets
9.2.2 Key Players in Down Markets
9.2.3 Downstream Market Trend Analysis
9.2.4 Sales Channel, Distributors, Traders and Dealers
10 Research Findings and Conclusion
List of Tables and Figures_x000D_
_x000D_
Figure Product Picture Selective Cox-2 Inhibitors_x000D_
Figure Market Concentration Ratio and Market Maturity Analysis of Selective Cox-2 Inhibitors_x000D_
Figure Bottom-up and Top-down Approaches for This Report_x000D_
Figure Part of Our External Database_x000D_
Figure Part of Our External Database_x000D_
Figure Key Executives Interviewed_x000D_
Table Global Selective Cox-2 Inhibitors Market Size by Big Type_x000D_
Figure Global Market Share of Selective Cox-2 Inhibitors by Big Type in 2023_x000D_
Figure Meloxicam Picture (2019-2024)_x000D_
Figure Celecoxib Picture (2019-2024)_x000D_
Figure Etoricoxib Picture (2019-2024)_x000D_
Figure Imrecoxib Picture (2019-2024)_x000D_
Figure Etodolac Picture (2019-2024)_x000D_
Figure Parecoxib Picture (2019-2024)_x000D_
Global Selective Cox-2 Inhibitors Market Size by Big Application_x000D_
Table Global Selective Cox-2 Inhibitors Market Size by Application_x000D_
Figure Global Selective Cox-2 Inhibitors Market Share by Big Application in 2023_x000D_
Figure Rheumatoid Arthritis Picture_x000D_
Figure Osteoarthritis Picture_x000D_
Figure Spondylosis Chronica Ankylopoietica Picture_x000D_
Figure Other Picture_x000D_
Table Global Selective Cox-2 Inhibitors Comparison by Regions (M USD) （2019-2029）_x000D_
Figure Global Selective Cox-2 Inhibitors Market Size (Million US$) (2019-2029)_x000D_
Figure North America Selective Cox-2 Inhibitors Revenue (Million US$) Growth Rate (2019-2029)_x000D_
Figure Europe Selective Cox-2 Inhibitors Revenue (Million US$) Growth Rate (2019-2029)_x000D_
Figure China Selective Cox-2 Inhibitors Revenue (Million US$) Growth Rate (2019-2029)_x000D_
Figure Japan Selective Cox-2 Inhibitors Revenue (Million US$) Growth Rate (2019-2029)_x000D_
Figure Southeast Asia Selective Cox-2 Inhibitors Revenue (Million US$) Growth Rate (2019-2029)_x000D_
Table Business Impact Assessment - Covid-19_x000D_
Table Market Trends and Selective Cox-2 Inhibitors Potential Opportunities in the COVID-19 Landscape_x000D_
Table Measures / Proposal against Covid-19_x000D_
Table Global Selective Cox-2 Inhibitors Sales by Manufacturer (2019-2024)_x000D_
Figure Global Selective Cox-2 Inhibitors Sales Market Share by Manufacturer in 2023_x000D_
Table Global Selective Cox-2 Inhibitors Revenue by Manufacturer (2019-2024)_x000D_
Figure Global Selective Cox-2 Inhibitors Revenue Market Share by Manufacturer in 2023 _x000D_
Table Global Selective Cox-2 Inhibitors Manufacturers Market Concentration Ratio (CR5 and HHI)_x000D_
Figure Top 5 Selective Cox-2 Inhibitors Manufacturer (Revenue) Market Share in 2023_x000D_
Figure Top 10 Selective Cox-2 Inhibitors Manufacturer (Revenue) Market Share in 2023_x000D_
Table Date of Key Manufacturers Enter into Selective Cox-2 Inhibitors Market_x000D_
Table Key Manufacturers Selective Cox-2 Inhibitors Product Type_x000D_
Table Mergers & Acquisitions Planning_x000D_
Table Boehringer-Ingelheim Company Profile_x000D_
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of Boehringer-Ingelheim_x000D_
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Company One 2019-2024_x000D_
Table Company One Main Business_x000D_
Table Company One Recent Development_x000D_
Table TerSera Therapeutics Company Profile_x000D_
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of TerSera Therapeutics_x000D_
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Company Two 2019-2024_x000D_
Table TerSera Therapeutics Recent Development_x000D_
Table Iroko Pharmaceuticals Company Profile_x000D_
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of Iroko Pharmaceuticals_x000D_
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Company Two 2019-2024_x000D_
Table Iroko Pharmaceuticals Main Business_x000D_
Table Iroko Pharmaceuticals Recent Development_x000D_
Table Apotex Company Profile_x000D_
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of Apotex_x000D_
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Company Two 2019-2024_x000D_
Table Apotex Main Business_x000D_
Table Apotex Recent Development_x000D_
Table Apotex Main Business_x000D_
Table Apotex Recent Development_x000D_
Table Yung Shin Pharmaceutical Company Profile_x000D_
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of Yung Shin Pharmaceutical_x000D_
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Company Two 2019-2024_x000D_
Table Yung Shin Pharmaceutical Main Business_x000D_
Table Yung Shin Pharmaceutical Recent Development_x000D_
Table Breckenridge Pharmaceutical Company Profile_x000D_
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of Breckenridge Pharmaceutical_x000D_
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Company Two 2019-2024_x000D_
Table Breckenridge Pharmaceutical Main Business_x000D_
Table Breckenridge Pharmaceutical Recent Development_x000D_
Table Meda Pharmaceuticals Company Profile_x000D_
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of Meda Pharmaceuticals_x000D_
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Company Two 2019-2024_x000D_
Table Meda Pharmaceuticals Main Business_x000D_
Table Meda Pharmaceuticals Recent Development_x000D_
Table Cipla Company Profile_x000D_
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of Cipla_x000D_
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Company Two 2019-2024_x000D_
Table Cipla Main Business_x000D_
Table Cipla Recent Development_x000D_
Table Glenmark Pharmaceuticals Company Profile_x000D_
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of Glenmark Pharmaceuticals_x000D_
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Company Two 2019-2024_x000D_
Table Glenmark Pharmaceuticals Main Business_x000D_
Table Glenmark Pharmaceuticals Recent Development_x000D_
Table Teva Company Profile_x000D_
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of Teva_x000D_
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Company Two 2019-2024_x000D_
Table Teva Main Business_x000D_
Table Teva Recent Development_x000D_
Table PuraCap Pharmaceutical Company Profile_x000D_
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of PuraCap Pharmaceutical_x000D_
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Company Two 2019-2024_x000D_
Table PuraCap Pharmaceutical Main Business_x000D_
Table PuraCap Pharmaceutical Recent Development_x000D_
Table Almirall Limited Company Profile_x000D_
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of Almirall Limited_x000D_
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Company Two 2019-2024_x000D_
Table Almirall Limited Main Business_x000D_
Table Almirall Limited Recent Development_x000D_
Table Lupin Pharmaceuticals Company Profile_x000D_
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of Lupin Pharmaceuticals_x000D_
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Company Two 2019-2024_x000D_
Table Lupin Pharmaceuticals Main Business_x000D_
Table Lupin Pharmaceuticals Recent Development_x000D_
Table Aurobindo Pharma Company Profile_x000D_
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of Aurobindo Pharma_x000D_
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Company Two 2019-2024_x000D_
Table Aurobindo Pharma Main Business_x000D_
Table Aurobindo Pharma Recent Development_x000D_
Table Mylan Company Profile_x000D_
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of Mylan_x000D_
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Company Two 2019-2024_x000D_
Table Mylan Main Business_x000D_
Table Mylan Recent Development_x000D_
Table Shire Pharmaceuticals Company Profile_x000D_
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of Shire Pharmaceuticals_x000D_
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Company Two 2019-2024_x000D_
Table Shire Pharmaceuticals Main Business_x000D_
Table Shire Pharmaceuticals Recent Development_x000D_
Table Bayer Company Profile_x000D_
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of Bayer_x000D_
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Company Two 2019-2024_x000D_
Table Bayer Main Business_x000D_
Table Bayer Recent Development_x000D_
Table Novacap Company Profile_x000D_
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of Novacap_x000D_
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Company Two 2019-2024_x000D_
Table Novacap Main Business_x000D_
Table Novacap Recent Development_x000D_
Table Abbott Company Profile_x000D_
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of Abbott_x000D_
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Company Two 2019-2024_x000D_
Table Abbott Main Business_x000D_
Table Abbott Recent Development_x000D_
Table Geri-Care Company Profile_x000D_
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of Geri-Care_x000D_
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Company Two 2019-2024_x000D_
Table Geri-Care Main Business_x000D_
Table Geri-Care Recent Development_x000D_
Table Perrigo Company Profile_x000D_
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of Perrigo_x000D_
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Company Two 2019-2024_x000D_
Table Perrigo Main Business_x000D_
Table Perrigo Recent Development_x000D_
Table Kopran Company Profile_x000D_
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of Kopran_x000D_
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Company Two 2019-2024_x000D_
Table Kopran Main Business_x000D_
Table Kopran Recent Development_x000D_
Table Merck Company Profile_x000D_
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of Merck_x000D_
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Company Two 2019-2024_x000D_
Table Merck Main Business_x000D_
Table Merck Recent Development_x000D_
Table Hengrui pharmaceutical Company Profile_x000D_
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of Hengrui pharmaceutical_x000D_
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Company Two 2019-2024_x000D_
Table Hengrui pharmaceutical Main Business_x000D_
Table Hengrui pharmaceutical Recent Development_x000D_
Table Kelun Group Company Profile_x000D_
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of Kelun Group_x000D_
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Company Two 2019-2024_x000D_
Table Kelun Group Main Business_x000D_
Table Kelun Group Recent Development_x000D_
Table Qilu Pharmaceutical Company Profile_x000D_
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of Qilu Pharmaceutical_x000D_
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Company Two 2019-2024_x000D_
Table Qilu Pharmaceutical Main Business_x000D_
Table Qilu Pharmaceutical Recent Development_x000D_
Table Taro Pharmaceuticals Company Profile_x000D_
Table Selective Cox-2 Inhibitors Product Introduction, Application and Specification of Taro Pharmaceuticals_x000D_
Table Selective Cox-2 Inhibitors Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Company Two 2019-2024_x000D_
Table Taro Pharmaceuticals Main Business_x000D_
Table Taro Pharmaceuticals Recent Development_x000D_
Figure Global Selective Cox-2 Inhibitors Sales and Growth Rate (2019-2024)_x000D_
Figure Global Selective Cox-2 Inhibitors Revenue and Growth Rate (2019-2024)_x000D_
Table Global Selective Cox-2 Inhibitors Sales by Regions (2019-2024)_x000D_
Figure Global Selective Cox-2 Inhibitors Sales Market Share by Regions in 2023_x000D_
Table Global Selective Cox-2 Inhibitors Revenue by Regions (2019-2024)_x000D_
Figure Global Selective Cox-2 Inhibitors Revenue Market Share by Regions in 2023_x000D_
Figure North America Selective Cox-2 Inhibitors Sales and Growth Rate (2019-2024)_x000D_
Figure Europe Selective Cox-2 Inhibitors Sales and Growth Rate (2019-2024)_x000D_
Figure China Selective Cox-2 Inhibitors Sales and Growth Rate (2019-2024)_x000D_
Figure Japan Selective Cox-2 Inhibitors Sales and Growth Rate (2019-2024)_x000D_
Figure Southeast Asia Selective Cox-2 Inhibitors Sales and Growth Rate (2019-2024)_x000D_
Figure Other Regions Selective Cox-2 Inhibitors Sales and Growth Rate (2019-2024)_x000D_
Table Global Selective Cox-2 Inhibitors Sales by Big Type (2019-2024)_x000D_
Table Global Selective Cox-2 Inhibitors Sales Market Share by Big Type (2019-2024)_x000D_
Figure Global Selective Cox-2 Inhibitors Sales Market Share by Big Type in 2023_x000D_
Table Global Selective Cox-2 Inhibitors Revenue by Big Type (2019-2024)_x000D_
Table Global Selective Cox-2 Inhibitors Revenue Market Share by Big Type (2019-2024)_x000D_
Table Global Selective Cox-2 Inhibitors Revenue Market Share by Big Type in 2023_x000D_
Figure Global Meloxicam Sales Growth Rate (2019-2024)_x000D_
Figure Global Meloxicam Price (2019-2024)_x000D_
Figure Global Celecoxib Sales Growth Rate (2019-2024)_x000D_
Figure Global Celecoxib Price (2019-2024)_x000D_
Figure Global Etoricoxib Sales Growth Rate (2019-2024)_x000D_
Figure Global Etoricoxib Price (2019-2024)_x000D_
Figure Global Imrecoxib Sales Growth Rate (2019-2024)_x000D_
Figure Global Imrecoxib Price (2019-2024)_x000D_
Figure Global Parecoxib Sales Growth Rate (2019-2024)_x000D_
Figure Global Parecoxib Price (2019-2024)_x000D_
Figure Global Other Sales Growth Rate (2019-2024)_x000D_
Table Global Selective Cox-2 Inhibitors Sales by Big Application (2019-2024)_x000D_
Table Global Selective Cox-2 Inhibitors Sales Market Share by Big Application (2019-2024)_x000D_
Figure Global Selective Cox-2 Inhibitors Sales Market Share by Big Application in 2023_x000D_
Figure Global Rheumatoid Arthritis Sales Growth Rate (2019-2024)_x000D_
Figure Global Osteoarthritis Sales Growth Rate (2019-2024)_x000D_
Figure Global Spondylosis Chronica Ankylopoietica Sales Growth Rate (2019-2024)_x000D_
Figure Global Other Sales Growth Rate (2019-2024)_x000D_
Figure Global Selective Cox-2 Inhibitors Sales and Growth Rate (2024-2029)_x000D_
Figure Global Selective Cox-2 Inhibitors Revenue and Growth Rate (2024-2029)_x000D_
Table Global Selective Cox-2 Inhibitors Sales Forecast by Regions (2024-2029)_x000D_
Table Global Selective Cox-2 Inhibitors Market Share Forecast by Regions (2024-2029)_x000D_
Figure North America Sales Selective Cox-2 Inhibitors Market Forecast (2024-2029)_x000D_
Figure Europe Sales Selective Cox-2 Inhibitors Market Forecast (2024-2029)_x000D_
Figure China Sales Selective Cox-2 Inhibitors Market Forecast (2024-2029)_x000D_
Figure Japan Sales Selective Cox-2 Inhibitors Market Forecast (2024-2029)_x000D_
Figure Southeast Asia Sales Selective Cox-2 Inhibitors Market Forecast (2024-2029)_x000D_
Figure Other Regions Sales Selective Cox-2 Inhibitors Market Forecast (2024-2029)_x000D_
Table Global Selective Cox-2 Inhibitors Sales Forecast by Type (2024-2029)_x000D_
Table Global Selective Cox-2 Inhibitors Market Share Forecast by Type (2024-2029)_x000D_
Table Global Selective Cox-2 Inhibitors Sales Forecast by Application (2024-2029)_x000D_
Table Global Selective Cox-2 Inhibitors Market Share Forecast by Application (2024-2029)_x000D_
Table Market Opportunities in Next Few Years_x000D_
Table Market Risks Analysis_x000D_
Table Market Drivers_x000D_
Figure Porter's Five Forces Analysis_x000D_
Table Macro Analysis of Upstream Markets_x000D_
Table Key Players in Upstream Markets_x000D_
Table Key Players of Upstream Markets_x000D_
Table Key Raw Materials_x000D_
Figure Price Trend of Key Raw Materials_x000D_
Table Key Suppliers of Raw Materials_x000D_
Figure Manufacturing Cost Structure of Selective Cox-2 Inhibitors_x000D_
Table Macro Analysis of Down Markets_x000D_
Table Key Players in Down Markets_x000D_
Table Key Players of Downstream Markets_x000D_
Figure Sales Channel_x000D_
Figure North America Selective Cox-2 Inhibitors Sales (K Units) Growth Rate Forecast (2024-2029)_x000D_
Figure North America Selective Cox-2 Inhibitors Revenue (Million US$) Growth Rate Forecast (2024-2029)_x000D_
Figure Europe Selective Cox-2 Inhibitors Sales (K Units) Growth Rate Forecast (2024-2029)_x000D_
Figure Europe Selective Cox-2 Inhibitors Revenue (Million US$) Growth Rate Forecast (2024-2029)_x000D_
Figure Japan Selective Cox-2 Inhibitors Production (K Units) Growth Rate Forecast (2024-2029)_x000D_
Figure Japan Selective Cox-2 Inhibitors Revenue (Million US$) Growth Rate Forecast (2024-2029)_x000D_
Figure China Selective Cox-2 Inhibitors Production (K Units) Growth Rate Forecast (2024-2029)_x000D_
Figure China Selective Cox-2 Inhibitors Revenue (Million US$) Growth Rate Forecast (2024-2029)_x000D_
Figure Methodology/Research Approach_x000D_
Figure Market Size Estimation_x000D_
Figure Author List_x000D_
Methodology/Research Approach
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.Research Programs/Design
| Historical Data (2015-2019) |
|
|
| Influencing Factors |
|
|
| Market Forecast (2021-2026) |
|
|
Market Size Estimation
Top-down and bottom-up approaches are used to validate the global Voluntary Carbon Offset market size market and estimate the market size for Company, regions segments, product segments and Application (end users).
The market estimations in this report are based on the marketed sale price of Voluntary Carbon Offset (excluding any discounts provided by the player, distributor, wholesaler or traders). The percentage splits, market share, and breakdowns of the product segments are derived on the basis of weights assigned to each of the segments on the basis of their utilization rate and average sale price. The regional splits of the overall Voluntary Carbon Offset market and its sub-segments are based on the percentage adoption or utilization of the given product in the respective region or country.
Major Company in the market is identified through secondary research and their market revenues determined through primary and secondary research. Secondary research included the research of the annual and financial reports of the top Company; whereas, primary research included extensive interviews of key opinion leaders and industry experts such as experienced front-line staff, directors, CEOs and marketing executives. The percentage splits, market share, Growth Rate and breakdowns of the product markets are determined through using secondary sources and verified through the primary sources.
All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or other factors are not accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Market Intellix and presented in this report
The following figure shows an illustrative representation of the overall market size estimation process used for this study.
Market Breakdown and Data Triangulation
After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation, extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
Data Source
Secondary Sources
Secondary sources include such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, etc. This research study involves the usage of widespread secondary sources, directories, databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), and TRADING ECONOMICS, and News Network, statista, Federal Reserve Economic Data, annual reports, BIS Statistics, ICIS; company house documents; CAS(American Chemical Society); investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and Hospitals study of the Voluntary Carbon Offset market. It was also used to obtain important information about the top companies, market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives.
| Market Size |
|
|
| Market Position of Top Company |
|
|
| Qualitative Analysis |
|
|
Primary Sources
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product Company (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.
The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end use (product buyers), and related key executives from various key companies and organizations operating in the global market.
Primary research was conducted to identify segmentation Type, product price range, product Application, key Company, raw materials supply and the downstream demand, industry status and outlook, and key market dynamics such as risks, influence factors, opportunities, market barriers, industry trends, and key player strategies.
Key Executives Interviewed
Key Data Information from Primary Sources
| Primary Sources | Parameters | Key Data |
| Market Segments(by Application, by Type) |
|
|
| Total Market |
|
|